WO1998029409A1 - Sels d'addition acides de compose de piperidine optiquement actif et procede de production associe - Google Patents
Sels d'addition acides de compose de piperidine optiquement actif et procede de production associe Download PDFInfo
- Publication number
- WO1998029409A1 WO1998029409A1 PCT/JP1997/004826 JP9704826W WO9829409A1 WO 1998029409 A1 WO1998029409 A1 WO 1998029409A1 JP 9704826 W JP9704826 W JP 9704826W WO 9829409 A1 WO9829409 A1 WO 9829409A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- acid
- optically active
- pyridyl
- methoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
Definitions
- the present invention relates to benzenesulfonate or benzoic acid of (S) -4- [4-[(4-chlorophenyl) (2-pyridyl) methoxy] piperidino] butanoic acid having excellent antihistamine activity and antiallergic activity.
- the present invention relates to an optical resolution method of 4-[(4-chlorophenyl) (2-pyridyl) methoxy] piperidine, which is important as a salt thereof, its production method and its racemic intermediate.
- the acid addition salt has low hygroscopicity and is excellent in physicochemical stability, so that it is a compound particularly suitable as a pharmaceutical.
- the present invention also relates to a pharmaceutical composition comprising these as an active ingredient.
- A represents a lower alkyl group, a hydroxyl group, a lower alkoxy group, an amino group, a lower alkylamino group, a phenyl group, or a lower alkyl-substituted phenyl group, or a piperidine compound (II) represented by Salt minimizes secondary effects, such as central nervous system irritation or depression, often seen with conventional antihistamines.
- sneezing, nasal discharge, cough, and bronchial asthma caused by upper respiratory tract inflammation, such as allergic rhinitis, common cold such as rash, eczema, and dermatitis. It is expected as a medicine.
- optical isomer In general, it is known that pharmacological activity and safety differ among optical isomers, and that metabolic rate and protein binding rate also differ (Pharmacia, 25 (4), 31-336, 1989). Therefore, it is necessary to provide pharmacologically favorable optical isomers with high optical purity in order to be a pharmaceutical. In addition, in order to ensure a high quality of the optical isomer as a drug, it is desired that the optical isomer has properties excellent in physicochemical stability.
- the present invention relates to a benzenesulfonate and a benzoate of an optically active piperidine compound (I) having an absolute configuration represented by (S).
- the second invention is directed to a benzene compound of the optically active piperidine compound, wherein the optically active piperidine compound represented by the formula (I) and having an absolute configuration of (S) and benzenesulfonic acid or benzoic acid is subjected to a salt-forming reaction.
- the present invention relates to a method for producing a sulfonate and a benzoate.
- the third invention relates to (S) -4- [4-[((4-monophenyl) (2-pyridyl) methoxy] piperidino] butanoic acid benzenesulfonate or benzoate as an effective ingredient.
- Pharmaceutical compositions comprising:
- (Sat) 14 1 [(4-chlorophenyl) (2-pyridyl) methoxy] piperidine is added to an optically active propionic acid compound (VII) or an optically active N represented by the formula (VII).
- an optically active propionic acid compound (VII) or an optically active N represented by the formula (VII) is added to an optically active propionic acid compound (VII) or an optically active N represented by the formula (VII).
- one diastereomer salt is separated and collected, and then the salt is decomposed to obtain (S) —4— [( (4-Phenyl phenyl) (2-pyridyl) methoxy] Piperidine with formula (V):
- R represents a lower alkyl group such as a methyl group or an ethyl group
- W represents a removable group such as a halogen atom or a reactive ester group such as a methanesulfonyl group or a p-toluenesulfonyl group.
- HX represents benzenesulfonic acid or benzoic acid
- * has the same meaning as described above, and can be produced by the method represented by the following formula (hereinafter, referred to as a salt forming reaction).
- benzenesulfonic acid or benzoic acid is used in an amount of from 0.8 to 2.5 times, preferably from 0.9 to 1.2 times, per mole of (S) -piberidine compound (I). It can be performed using moles.
- the solvent used for the salt-forming reaction is not particularly limited as long as it is a solvent that does not participate in the reaction. Examples of such solvents include ditolyls such as acetate and propionitol, methyl acetate and ethyl acetate.
- esters such as methanol, ethanol, 1-propanol and 2-propanol, acetone, dimethylformamide and the like, preferably ethanol, 2-propanol, acetate and acetic acid Etil.
- the above-mentioned solvents may be used alone, or two or more arbitrary solvents may be used as a mixture.
- the amount of the solvent used in the salt formation reaction is usually 0.5 to 30 G, preferably 0.8 to 20 Q, per 1 mol of the (S) -piperidine compound (I), More preferably, it is 1 to 10 ⁇ .
- the temperature of the salt formation reaction is, for example, 5 to 50 ° C, preferably 10 to 35 ° C, and the temperature at the time of salt precipitation is, for example, -30 ° C to 30 ° C, preferably 110 ° C. C to 15 ° C.
- the method of addition is not particularly limited. For example, a method in which benzenesulfonic acid or benzoic acid is dissolved in a solvent and added to a mixture of (S) -piperidine compound (I) and a solvent may be mentioned. it can.
- the salt of the (S) -piperidine compound (I) to be formed can be easily obtained by fractionating by filtration, centrifugation, etc., followed by washing and drying as appropriate according to a conventional method in this technical field. .
- reaction formula (2) Reaction formula (2)
- W is a removable group, for example, a halogen atom such as a chlorine atom, a bromine atom or an iodine atom, or a reactive ester group such as a methanesulfonyloxy group or a p-toluenesulfonyloxy group, and R is A lower alkyl group such as methyl and ethyl, and * is as defined above.
- halogen atom such as a chlorine atom, a bromine atom or an iodine atom
- a reactive ester group such as a methanesulfonyloxy group or a p-toluenesulfonyloxy group
- R is A lower alkyl group such as methyl and ethyl, and * is as defined above.
- Step A is an N-alkylation reaction of the (S) -piperidine intermediate (IV), and is preferably 1 to 3 moles of the ester (V) per 1 mole of the (S) -piperidine intermediate (IV). Can be carried out using 1 to 1.5 times mole.
- the above reaction is performed in an inert solvent. Suitable solvents include, for example, water; lower alcohols such as methanol, ethanol, propanol, and butanol; ditriles such as acetonitrile and propionitol; benzene, toluene, xylene and the like.
- Aromatic hydrocarbons such as 1,4-dioxane and tetrahydrofuran; ketones such as acetone, ethyl methyl ketone and methyl isobutyl ketone; amides such as N, N-dimethylformamide; And preferably with water, acetate, triacetone, acetone, N, N-dimethylformamide. is there. These may be used alone or as a mixture of two or more arbitrary solvents.
- Suitable bases include, for example, alkali metal hydroxides such as sodium hydroxide; alkaline earth metal hydroxides such as calcium hydroxide; Alkali earth metal carbonates such as calcium carbonate; Alkali metal acid carbonates such as sodium bicarbonate; Alkali metal hydrogen such as sodium hydride Chloride; alkaline metal hydrides such as calcium hydride; alkali metal alkoxides such as sodium methoxide; trialkylamines such as triethylamine; pyridine compounds; and the like, preferably sodium carbonate.
- Potassium carbonate, sodium bicarbonate or potassium bicarbonate sodium bicarbonate or potassium bicarbonate.
- bases are monovalent, they are used in an amount of 1 to 3 moles, preferably 5 moles, per mole of the (S) -piperidine intermediate (IV). If it is a divalent base, it is used in a molar amount of 0.5 to 5 times, preferably 0.6 to 1 times.
- the reaction can be carried out at the reflux temperature of the reaction mixture, for example 5 to 150 ° C, preferably 20 to 100 ° C.
- the reaction time is 2 to 24 hours.
- Step B is a hydrolysis reaction of (S) -ester (VI) in which an inorganic base such as sodium hydroxide or potassium hydroxide is dissolved in an aqueous alcohol such as aqueous methanol or aqueous ethanol. It can be carried out using 1 to 5 moles, preferably 1 to 3 moles, per 1 mole of the ester (VI).
- the reaction temperature is, for example, 5 to 90 ° C, preferably 15 to 70 ° C.
- the reaction time is ⁇ to 10 hours.
- the (S) -piperidine compound (I) can be produced by neutralizing the reaction solution with a mineral acid such as hydrochloric acid or sulfuric acid or an organic acid such as acetic acid or oxalic acid.
- methods for obtaining an optically active substance include methods such as asymmetric synthesis, optical resolution using an enzyme such as fractional crystallization lipase, and fractionation using an optical resolution column.
- the following reaction formula (3) is used:
- the optical compound obtained by preliminarily optically resolving the ( ⁇ ) -4-((4-chlorophenyl) (2-pyridyl) methoxy) piperidine represented by the formula (III), which is the starting compound, is obtained.
- Active (S) -4-([4-chlorophenyl) (2-pyridyl) methoxy] piperidine (IV) may be used as an intermediate.
- optical division can be efficiently performed by the following method. That is, formula (III):
- Y represents a hydrogen atom or a halogen atom
- ⁇ represents a lower alkoxy group
- * represents an asymmetric carbon
- optically active propyl acetate compound (VII) used as the optical resolving agent include the following compounds
- (VII) there may be mentioned compounds wherein ⁇ is a hydrogen atom or a chlorine atom and ⁇ is a methoxy group.
- Preferred examples of these are (2R, 3R) -2-hydroxy-13- (4-methoxyphenyl) 13- (2-nitro-5-chlorophenylthio) p , And (2R, 3R) -12-hydroxy-13- (4-methoxyphenyl) -13- (2-nitrophenylthio) propionic acid, among which (2) R, 3R) -2-Hydroxy-1-3- (4-methoxyphenyl) 1-3- (2-nitro-5-chlorophenylthio) propionic acid is preferred.
- the acetyl group of the optically active N-amino acid used as an optical resolving agent includes an aliphatic acetyl group such as acetyl and propionyl, an aromatic acetyl group such as thosyl group, and a benzyloxyl propyl group. Such an aralkyl group is used.
- Optically active N-acyl-amino acids are obtained by acylating neutral, acidic and basic various amino acids and unnatural D-amino acids, which are constituents of proteins, by a conventional method.
- the amino acid preferably include phenylalanine, L-isocyanate, L-glutamic acid, L-methine, L-valine, L-threonine, and D-phenyldaricin.
- optically active ⁇ -acyl-amino acids include ⁇ -acetyl-L-phenylalanine, ⁇ -acetyl-L-leucine, ⁇ -benzyl-l-carbonyl, —-benzyl-l-carbonyl, and ⁇ -benzyl-l-xycarbonyl.
- Examples include ruthyl-valine, di-benzyloxycarbonyl-L-threonine, and dibenzylbenzylxicarbone-L-serine, and more preferably diacetyl-phenyl-phenylene.
- the amount of the optically active propionic acid compound (VII) of the formula (VII) or the optically active hydroxyamino acid used as the optical resolving agent is not particularly limited, but the racemic piperidine of the formula (III) It is preferred to use 0.5 to 1.5 moles, preferably 0.6 to 1.1 moles, per 1 mole of the intermediate (III).
- racemic piperidine intermediate (III) of the formula (III) used as a raw material in the present invention an equivalent mixture of the (S) type isomer and the (R) type isomer is sufficient, but the mixing ratio of the isomers is as follows: However, the mixture may not necessarily be the same amount, and may be a mixture containing one of them in a large amount.
- an acid addition salt such as a hydrochloride
- an alkali suitable for the reaction system for example, sodium hydroxide
- Addition of a base such as (rium) causes salt exchange to be a free piperidine compound.
- optically active propionic acid compound (VII) or the optically active N-acyl-amino acid of the formula (VII) a salt with a base can be used.
- an acid such as hydrochloric acid is added to the reaction system.
- a free optically active propionic acid compound (VII) or a free optically active N-acyl-amino acid respectively.
- Solvents used for optical resolution of the racemic piperidine intermediate (III) include alcohols such as methanol, ethanol and propanol; ketones such as acetone and methyl ketone; methyl acetate and acetic acid Esters of carboxylic acids such as ethyl; nitritols such as acetate and propionitol; ethers such as dioxane and tetrahydrofuran; amides such as dimethylformamide Or water and the like, particularly preferably esters, nitriles, alcohols or water, and particularly preferably alcohols or water. These solvents may be used alone, or if necessary, may be used in a mixture of two or more kinds at an appropriate ratio.
- a mixed solvent of alcohols and water is preferable.
- the amount of the solvent to be used is not particularly limited, but it may be, for example, 2 to 50 parts by weight, preferably 5 to 50 parts by weight, per 1 part by weight of the racemic piperidine intermediate (III).
- the mother liquor after separation of the hardly soluble diastereomer is concentrated, and the diastereomer salt which has not been precipitated as the hardly soluble diastereomer salt is separated and collected, and then the salt is decomposed, or After separation of the salt, the mother liquor may be extracted with a suitable organic solvent to recover the optically active piperidine intermediate (IV) as an enantiomer.
- the purity of the diastereomer salt separated and collected can be further increased by recrystallization if necessary.
- the diastereomer salt thus collected can be eliminated from the salt by a known salt decomposition method to obtain the desired optically active piperidine intermediate (IV).
- a suitable solvent for example, a mixed solution of water and dimethylformamide
- a suitable alkali for example, sodium hydroxide, potassium hydroxide, etc.
- a suitable extraction solvent for example, Dimethyl ether, ethyl acetate, chloroform, methyl chloride, toluene, etc.
- the aqueous layer is treated with a suitable mineral acid (eg, hydrochloric acid, sulfuric acid, etc.), and then extracted with a suitable solvent (eg, getyl ether, ethyl acetate, chloroform, methylene chloride, toluene, etc.).
- a suitable mineral acid eg, hydrochloric acid, sulfuric acid, etc.
- a suitable solvent eg, getyl ether, ethyl acetate, chloroform, methylene chloride, toluene, etc.
- a sparingly soluble diastereomer salt is defined as a pair of diastereomer salts.
- a diastereomer salt having lower solubility in a solvent is meant.
- the raw material of the racemic piperidine intermediate (III) of the formula (III) is described in JP-A-2-25465.
- the optically active propionic acid compound (VII) of the formula (VII), which is an optical resolving agent, can be produced, for example, according to the method described in JP-B-63-139944.
- the maximum inhibition rate in this test is estimated to be about 70%, and when compared with the 50% (ie, 35%) inhibitory dose, (S) -ester is about 100 times stronger than (R) -ester. Showed an effect. From these results, a clear difference in pharmacological action was observed between the optical isomers, and it was confirmed that (S) -ester was superior to (R) -ester. However, the above (S) -ester is hygroscopic, as shown in the stability test results (Table 4) described later, and (S) -piperid of formula (I), which is a metabolite of (S) -S. Gin compounds exhibit the same pharmacological action as (S) -esters, but themselves are compounds with extremely poor crystallinity, and are usually obtained as candy, ensuring and maintaining high quality as pharmaceuticals. Was difficult.
- the (S) -piperidine compound (I) of the formula (I) was dissolved in an organic solvent, added with an acid shown in Table 3, homogenized, and allowed to stand. If no precipitate was obtained, the solvent was distilled off, a poorly soluble solvent was added, and the mixture was allowed to stand again. Except when the acid addition salt was oily or candy-like, the obtained solid was collected by filtration and dried under reduced pressure. As shown in Table 3, the properties of the obtained various acid addition salts were mostly oily or hygroscopic crystals.
- Each of the above compounds was pulverized and passed through a 500 nm sieve to obtain a test sample. Each sample was divided into glass dishes and stored at 40 ° C and 75% humidity. After one month, the samples were taken out and the amount of related substances and (R) -body content by racemization were measured. Was compared with the content at the start of the test.
- the sample was dissolved in the mobile phase and prepared so that about 0.1% of the sample was contained in 1 ml of this solution.
- the percentage of each peak area was measured by liquid chromatography using the sample solution 2 and liquid chromatography.
- UV absorption spectrophotometer (225 nm)
- Benzene sulfonate, benzoate A mixture of 0.1 M potassium dihydrogen phosphate buffer (adjusted to pH 5.8 with 0.1 N sodium hydroxide solution) and acetate nitrile (7 2 : 2 8)
- (S) -ester A mixture of 0.02 M potassium dihydrogen phosphate buffer (adjusted to pH 4.6 with 0.1 N sodium hydroxide solution) and ethanol (100: 13) benzenesulfonate, benzoic acid Acid salt: 0.02 M dihydrogen phosphate buffer solution (adjusted to pH 5.5 with 0.1 N sodium hydroxide solution) and acetonitrile mixture (100: 1 6) Flow rate: 0.9 ml / min Area measurement range: (S) Approximately twice the retention time of body Retention time: (R) Approx. 7 to 10 min (S) Approx. 13 to 15 min Table 4
- the benzenesulfonate and benzoate of the (S) -piperidine compound (I) are more excellent optically active substances having antihistamine activity and antiallergic activity, and are active in vivo. It has properties that are suitable as pharmaceuticals, because it acts as a drug and exhibits excellent physicochemical stability.
- the precipitated crystals are collected by filtration, washed with ethanol, dried at 50 ° C under reduced pressure, and dried with (S) -4-[(4-chlorophenyl) (2-pyridyl) methoxy] piperidine and (2 (R, 3 R) — 2-Hydroxy-3- (4-methoxyphenyl) -3- (2-Nitro-1-5-chlorophenyl) 0.97 g of crude crystals of a salt with propionic acid were obtained.
- (S) -4-[(4-chlorophenyl) (2-pyridyl) methoxy] piperidine and (2 (R, 3 R) — 2-Hydroxy-3- (4-methoxyphenyl) -3- (2-Nitro-1-5-chlorophenyl) 0.97 g of crude crystals of a salt with propionic acid were obtained.
- diastereomer salt refers to e.e. of 4-[(4-chlorophenyl) (2-pyridyl) methoxy] piperidine contained in the salt.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/331,792 US6307052B1 (en) | 1996-12-26 | 1997-12-25 | Acid-addition salts of optically active piperidine compound and process for producing the same |
EP97949235A EP0949260B1 (en) | 1996-12-26 | 1997-12-25 | Acid-addition salts of optically active piperidine compound and process for producing the same |
CA002275987A CA2275987C (en) | 1996-12-26 | 1997-12-25 | Acid addition salt of optically active piperidine compound and process for preparing the same |
DK97949235T DK0949260T3 (da) | 1996-12-26 | 1997-12-25 | Syreadditionssalte af en optisk aktiv piperidinforbindelse og fremgangsmåde til fremstilling deraf |
DE69712784T DE69712784T2 (de) | 1996-12-26 | 1997-12-25 | Säureadditionssalze einer optisch aktiven piperidinverbindung und verfahren zu seiner herstellung |
AT97949235T ATE217872T1 (de) | 1996-12-26 | 1997-12-25 | Säureadditionssalze einer optisch aktiven piperidinverbindung und verfahren zu seiner herstellung |
KR10-1999-7005802A KR100515227B1 (ko) | 1996-12-26 | 1997-12-25 | 광학 활성 피페리딘 화합물의 산부가염 및 그의 제조 방법 |
AU78906/98A AU7890698A (en) | 1996-12-26 | 1997-12-25 | Acid-addition salts of optically active piperidine compounds and process for producing the same |
HK00101619A HK1022477A1 (en) | 1996-12-26 | 2000-03-16 | Acid-addition salts of optically active piperidine compound and process for producing the same |
US10/771,361 US7282589B2 (en) | 1996-12-26 | 2004-02-05 | Acid addition salt of optically active piperidine compound and process for preparing the same |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP34789596 | 1996-12-26 | ||
JP34785196A JP3157117B2 (ja) | 1996-12-26 | 1996-12-26 | ピペリジン誘導体の光学分割方法 |
JP8/347851 | 1996-12-26 | ||
JP8/347895 | 1996-12-26 | ||
JP8/347853 | 1996-12-26 | ||
JP34785396A JP3157118B2 (ja) | 1996-12-26 | 1996-12-26 | アシルアミノ酸を用いるピペリジン誘導体の光学分割方法 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09331792 A-371-Of-International | 1997-12-25 | ||
US09/331,792 A-371-Of-International US6307052B1 (en) | 1996-12-26 | 1997-12-25 | Acid-addition salts of optically active piperidine compound and process for producing the same |
US09/949,809 Division US6780877B2 (en) | 1996-12-26 | 2001-09-12 | Acid addition salt of optically active piperidine compound and process for preparing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998029409A1 true WO1998029409A1 (fr) | 1998-07-09 |
Family
ID=27341269
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1997/004826 WO1998029409A1 (fr) | 1996-12-26 | 1997-12-25 | Sels d'addition acides de compose de piperidine optiquement actif et procede de production associe |
Country Status (16)
Country | Link |
---|---|
US (3) | US6307052B1 (ja) |
EP (1) | EP0949260B1 (ja) |
KR (1) | KR100515227B1 (ja) |
CN (2) | CN1098262C (ja) |
AT (1) | ATE217872T1 (ja) |
AU (1) | AU7890698A (ja) |
CA (1) | CA2275987C (ja) |
DE (1) | DE69712784T2 (ja) |
DK (1) | DK0949260T3 (ja) |
ES (1) | ES2173499T3 (ja) |
HK (1) | HK1022477A1 (ja) |
ID (1) | ID21985A (ja) |
MY (1) | MY118016A (ja) |
PT (1) | PT949260E (ja) |
TW (1) | TW486475B (ja) |
WO (1) | WO1998029409A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004011001A1 (ja) | 2002-07-31 | 2004-02-05 | Senju Pharmaceutical Co., Ltd. | 水性液剤および光安定化された水性液剤 |
JP2010529187A (ja) * | 2007-06-11 | 2010-08-26 | ハンミ ファーム. シーオー., エルティーディー. | ベポタスチンの製造方法及びそれに用いられる中間体 |
EP2222639A1 (en) * | 2007-11-21 | 2010-09-01 | Decode Genetics EHF | Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders |
JP2011195500A (ja) * | 2010-03-19 | 2011-10-06 | Tokuyama Corp | (s)−4−[4−[(4−クロロフェニル)(2−ピリジル)メトキシ]ピペリジノ]ブタン酸一ベンゼンスルホン酸塩の製造方法 |
WO2012094283A2 (en) | 2011-01-04 | 2012-07-12 | Ista Pharmaceuticals, Inc. | Bepotastine compositions |
US8877168B1 (en) | 2002-07-31 | 2014-11-04 | Senju Pharmaceuticals Co., Ltd. | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1311482B1 (en) * | 2000-08-08 | 2007-02-21 | Ortho-McNeil Pharmaceutical, Inc. | Non-imidazole aryloxypiperidines as h3 receptor ligands |
AU2002347906A2 (en) * | 2001-10-16 | 2003-04-28 | Hypnion, Inc. | Treatment of CNS disorders using CNS target modulators |
US7355042B2 (en) | 2001-10-16 | 2008-04-08 | Hypnion, Inc. | Treatment of CNS disorders using CNS target modulators |
US7189757B2 (en) | 2001-10-16 | 2007-03-13 | Hypnion, Inc. | Treatment of sleep disorders using CNS target modulators |
US20040171836A1 (en) * | 2001-12-21 | 2004-09-02 | Toshihiro Fujino | Method for producing optical-active cis-piperidine derivatives |
US7250487B2 (en) * | 2002-01-17 | 2007-07-31 | Arkema France | Supramolecular polymers |
JP3746063B2 (ja) | 2002-08-29 | 2006-02-15 | 大正製薬株式会社 | 4−フルオロ−2−シアノピロリジン誘導体ベンゼンスルホン酸塩 |
ES2452822T3 (es) | 2006-06-28 | 2014-04-02 | Amgen Inc. | Inhibidores del transportador 1 de glicina |
KR100878698B1 (ko) | 2007-04-05 | 2009-01-13 | 한미약품 주식회사 | 결정형의 베포타스틴 금속염 수화물, 이의 제조방법 및이를 포함하는 약학 조성물 |
KR101307712B1 (ko) * | 2008-12-02 | 2013-09-11 | 한미사이언스 주식회사 | 결정형의 베포타스틴 금속염 수화물, 이의 제조방법 및 이를 포함하는 약학 조성물 |
KR101132949B1 (ko) * | 2009-09-08 | 2012-04-10 | 경희대학교 산학협력단 | 베포타스틴 살리실산염, 이의 제조방법 및 이를 유효성분으로 포함하는 항히스타민 또는 항알레르기용 약학적 조성물 |
KR101146009B1 (ko) | 2009-10-01 | 2012-05-15 | 동인화학 주식회사 | 광학 분리에 의한 활성 피페리딘 화합물의 제조방법 |
CN101928278B (zh) * | 2010-08-23 | 2013-06-05 | 浙江燎原药业有限公司 | (s)-4-[(4-氯苯基)(吡啶-2-基)甲氧基]哌啶羟基苯丙酸盐及其应用 |
CN102675283B (zh) * | 2012-05-17 | 2013-08-14 | 上海右手医药科技开发有限公司 | 一种酸性条件下缩合制备贝托斯汀的新方法 |
TWI455933B (zh) * | 2012-08-10 | 2014-10-11 | Everlight Chem Ind Corp | 貝他斯汀或其苯磺酸鹽之製法及其使用之中間體 |
US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
CN105026369A (zh) | 2013-02-28 | 2015-11-04 | 德米拉股份有限公司 | 格隆铵盐 |
US8558008B2 (en) | 2013-02-28 | 2013-10-15 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
CN104031029A (zh) * | 2013-03-08 | 2014-09-10 | 重庆华邦制药有限公司 | 单一光学异构体的2-[(4-氯苯基)(哌啶-4-氧基)甲基]吡啶的合成方法 |
CN104119314B (zh) * | 2013-04-23 | 2018-01-12 | 重庆华邦制药有限公司 | 一种稳定的苯磺酸贝他斯汀晶体及其制备方法 |
CN104003978B (zh) * | 2014-06-18 | 2016-01-20 | 江苏联环药业股份有限公司 | 贝他斯汀或其消旋化合物的工业化制备方法 |
CN104151295B (zh) * | 2014-08-26 | 2015-12-30 | 山东川成医药股份有限公司 | 一种2-[(4-氯苯基)(4-哌啶基氧基)甲基]吡啶的合成方法 |
CN106117183B (zh) * | 2016-06-24 | 2019-08-02 | 合肥久诺医药科技有限公司 | 一种高纯度苯磺贝他斯汀的精制方法 |
CN106938995B (zh) * | 2017-01-17 | 2019-05-28 | 宜昌人福药业有限责任公司 | 一种眼科药物苯磺酸贝他斯汀的不对称合成方法 |
CN106946847B (zh) * | 2017-03-27 | 2019-06-21 | 福建省微生物研究所 | 一种贝他斯汀重要中间体的制备方法 |
CN108727335A (zh) * | 2018-08-07 | 2018-11-02 | 福建省微生物研究所 | 一种苯磺贝他斯汀的纯化方法 |
CN111116556B (zh) * | 2019-12-26 | 2021-11-02 | 北京鑫开元医药科技有限公司 | 一种(r)-2-[(4-氯苯基)(4-哌啶氧基)甲基]吡啶的制备方法 |
CN113480521B (zh) * | 2021-07-12 | 2024-04-16 | 成都丽凯手性技术有限公司 | 一种苯磺酸贝他斯汀全合成方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6413090A (en) * | 1987-07-07 | 1989-01-17 | Ube Industries | Xanthine derivative |
JPH01242574A (ja) * | 1988-03-25 | 1989-09-27 | Ube Ind Ltd | 含窒素縮合環を有するピペリジン及びピペラジン誘導体、その製造方法並びにそれを含む薬学的組成物 |
JPH04182467A (ja) * | 1990-11-15 | 1992-06-30 | Ube Ind Ltd | ジアリールメトキシピペリジン誘導体 |
JPH05345759A (ja) * | 1991-08-08 | 1993-12-27 | Kaken Pharmaceut Co Ltd | ピペリジン誘導体 |
JPH06135958A (ja) * | 1992-10-28 | 1994-05-17 | Tanabe Seiyaku Co Ltd | ベンゾシクロヘプテン誘導体及びその製法 |
JPH06239742A (ja) * | 1992-12-03 | 1994-08-30 | Tanabe Seiyaku Co Ltd | 排尿障害の予防・治療剤 |
JPH06336480A (ja) * | 1993-05-28 | 1994-12-06 | Ube Ind Ltd | ピペリジン中間体の精製法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5345759A (en) * | 1976-10-07 | 1978-04-24 | Takasago Thermal Eng Co Lts | Formation method for spot clean zone |
JPS6336480A (ja) * | 1986-07-31 | 1988-02-17 | Hitachi Seiki Co Ltd | 部品図の寸法表示自動作画装置 |
US4730827A (en) * | 1986-11-21 | 1988-03-15 | Williams George R | Hand rehabilitation device |
JPS63225465A (ja) | 1987-03-13 | 1988-09-20 | Jeol Ltd | 走査電子顕微鏡等の集束レンズ |
JPS6413090U (ja) * | 1987-07-13 | 1989-01-24 | ||
US4929618A (en) * | 1988-03-25 | 1990-05-29 | Ube Industries, Ltd. | Piperdine and piperazine derivatives, and antihistaminic pharmaceutical compositions containing the same |
FR2637285B1 (fr) * | 1988-10-03 | 1991-04-12 | Synthelabo | Procede de preparation de derives de l'acide propionique et produits obtenus |
CA2035147A1 (en) * | 1990-02-08 | 1991-08-09 | Kousuke Yasuda | Thiazine (or oxazine) derivatives and preparation thereof |
JPH04225465A (ja) | 1990-12-27 | 1992-08-14 | Hitachi Ltd | 文書作成装置 |
JPH1025465A (ja) | 1996-07-10 | 1998-01-27 | Toshiba Chem Corp | 耐熱性フィルム接着剤組成物 |
JPH10182635A (ja) * | 1996-12-26 | 1998-07-07 | Ube Ind Ltd | 光学活性ピペリジン誘導体及びその製造方法 |
IT1293941B1 (it) | 1997-02-13 | 1999-03-11 | Orthofix Srl | Attrezzo ortopedico particolarmente per la correzione chirurgica di deformazioni ossee |
JP3252741B2 (ja) * | 1997-02-21 | 2002-02-04 | 宇部興産株式会社 | 光学活性ピペリジン化合物のラセミ化方法 |
US6319176B1 (en) * | 1999-07-28 | 2001-11-20 | Hampton Fitness Products, Ltd. | Weightlifting plate |
USD474517S1 (en) * | 2002-01-18 | 2003-05-13 | Technical Knockout, Inc. | Barbell weight plate |
-
1997
- 1997-12-24 TW TW086119702A patent/TW486475B/zh not_active IP Right Cessation
- 1997-12-25 ID IDW990748A patent/ID21985A/id unknown
- 1997-12-25 KR KR10-1999-7005802A patent/KR100515227B1/ko not_active IP Right Cessation
- 1997-12-25 WO PCT/JP1997/004826 patent/WO1998029409A1/ja active IP Right Grant
- 1997-12-25 AT AT97949235T patent/ATE217872T1/de active
- 1997-12-25 DK DK97949235T patent/DK0949260T3/da active
- 1997-12-25 EP EP97949235A patent/EP0949260B1/en not_active Expired - Lifetime
- 1997-12-25 DE DE69712784T patent/DE69712784T2/de not_active Expired - Lifetime
- 1997-12-25 CA CA002275987A patent/CA2275987C/en not_active Expired - Lifetime
- 1997-12-25 ES ES97949235T patent/ES2173499T3/es not_active Expired - Lifetime
- 1997-12-25 US US09/331,792 patent/US6307052B1/en not_active Expired - Lifetime
- 1997-12-25 AU AU78906/98A patent/AU7890698A/en not_active Abandoned
- 1997-12-25 CN CN97181039A patent/CN1098262C/zh not_active Expired - Lifetime
- 1997-12-25 PT PT97949235T patent/PT949260E/pt unknown
- 1997-12-26 MY MYPI97006328A patent/MY118016A/en unknown
-
2000
- 2000-03-16 HK HK00101619A patent/HK1022477A1/xx not_active IP Right Cessation
-
2001
- 2001-09-12 US US09/949,809 patent/US6780877B2/en not_active Expired - Lifetime
-
2002
- 2002-07-30 CN CNB021271631A patent/CN1231478C/zh not_active Expired - Lifetime
-
2004
- 2004-02-05 US US10/771,361 patent/US7282589B2/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6413090A (en) * | 1987-07-07 | 1989-01-17 | Ube Industries | Xanthine derivative |
JPH01242574A (ja) * | 1988-03-25 | 1989-09-27 | Ube Ind Ltd | 含窒素縮合環を有するピペリジン及びピペラジン誘導体、その製造方法並びにそれを含む薬学的組成物 |
JPH04182467A (ja) * | 1990-11-15 | 1992-06-30 | Ube Ind Ltd | ジアリールメトキシピペリジン誘導体 |
JPH05345759A (ja) * | 1991-08-08 | 1993-12-27 | Kaken Pharmaceut Co Ltd | ピペリジン誘導体 |
JPH06135958A (ja) * | 1992-10-28 | 1994-05-17 | Tanabe Seiyaku Co Ltd | ベンゾシクロヘプテン誘導体及びその製法 |
JPH06239742A (ja) * | 1992-12-03 | 1994-08-30 | Tanabe Seiyaku Co Ltd | 排尿障害の予防・治療剤 |
JPH06336480A (ja) * | 1993-05-28 | 1994-12-06 | Ube Ind Ltd | ピペリジン中間体の精製法 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004011001A1 (ja) | 2002-07-31 | 2004-02-05 | Senju Pharmaceutical Co., Ltd. | 水性液剤および光安定化された水性液剤 |
KR101016595B1 (ko) * | 2002-07-31 | 2011-02-22 | 센주 세이야꾸 가부시키가이샤 | 수성액제 및 광안정화된 수성액제 |
US8784789B2 (en) | 2002-07-31 | 2014-07-22 | Senju Pharmaceutical Co., Ltd. | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
US8877168B1 (en) | 2002-07-31 | 2014-11-04 | Senju Pharmaceuticals Co., Ltd. | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
US8883825B2 (en) | 2002-07-31 | 2014-11-11 | Senju Pharmaceutical Co., Ltd. | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
US9849121B2 (en) | 2002-07-31 | 2017-12-26 | Senju Pharmaceutical Co., Ltd. | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
JP2010529187A (ja) * | 2007-06-11 | 2010-08-26 | ハンミ ファーム. シーオー., エルティーディー. | ベポタスチンの製造方法及びそれに用いられる中間体 |
EP2222639A1 (en) * | 2007-11-21 | 2010-09-01 | Decode Genetics EHF | Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders |
US8791267B2 (en) | 2007-11-21 | 2014-07-29 | Decode Genetics Ehf | Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disorders |
JP2011195500A (ja) * | 2010-03-19 | 2011-10-06 | Tokuyama Corp | (s)−4−[4−[(4−クロロフェニル)(2−ピリジル)メトキシ]ピペリジノ]ブタン酸一ベンゼンスルホン酸塩の製造方法 |
WO2012094283A2 (en) | 2011-01-04 | 2012-07-12 | Ista Pharmaceuticals, Inc. | Bepotastine compositions |
US10736841B2 (en) | 2011-01-04 | 2020-08-11 | Bausch & Lomb Incorporated | Bepotastine compositions |
Also Published As
Publication number | Publication date |
---|---|
DK0949260T3 (da) | 2002-09-09 |
EP0949260A1 (en) | 1999-10-13 |
CA2275987C (en) | 2006-12-19 |
ID21985A (id) | 1999-08-19 |
KR20000062337A (ko) | 2000-10-25 |
ATE217872T1 (de) | 2002-06-15 |
AU7890698A (en) | 1998-07-31 |
KR100515227B1 (ko) | 2005-09-16 |
US6780877B2 (en) | 2004-08-24 |
US7282589B2 (en) | 2007-10-16 |
CA2275987A1 (en) | 1998-07-09 |
PT949260E (pt) | 2002-09-30 |
DE69712784T2 (de) | 2002-11-21 |
CN1231478C (zh) | 2005-12-14 |
EP0949260A4 (en) | 2000-03-15 |
ES2173499T3 (es) | 2002-10-16 |
EP0949260B1 (en) | 2002-05-22 |
CN1098262C (zh) | 2003-01-08 |
US20040220226A1 (en) | 2004-11-04 |
MY118016A (en) | 2004-08-30 |
US20020026054A1 (en) | 2002-02-28 |
US6307052B1 (en) | 2001-10-23 |
CN1242013A (zh) | 2000-01-19 |
TW486475B (en) | 2002-05-11 |
DE69712784D1 (de) | 2002-06-27 |
HK1022477A1 (en) | 2000-08-11 |
CN1446812A (zh) | 2003-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998029409A1 (fr) | Sels d'addition acides de compose de piperidine optiquement actif et procede de production associe | |
JP5518928B2 (ja) | 光学活性ピペリジン誘導体の酸付加塩及びその製法 | |
US5512571A (en) | (-) 4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl!-hydra-zono!propanedinitrile | |
EP0149578B1 (fr) | Nouveaux dérivés de la xanthine, leur procédé de préparation et les compositions pharmaceutiques les renfermant | |
EP0281459B1 (fr) | Enantiomère dextrogyre de l'alpha-(tétrahydro-4,5,6,7 thiéno (3,2-c)pyridyl-5) (chloro-2 phényl)-acétate de méthyle, son procédé de préparation et les compositions pharmaceutiques le renfermant | |
EP0202164B1 (fr) | Dérivés de (benzoyl-4 pipéridino)-2 phenyl-1 alcanols, leur préparation et leur application en thérapeutique | |
EP0617028A1 (fr) | Enantiomères de la 1-(4-chlorophényl)phénylméthyl)-4-(4-méthylphényl)sulfonyl pipérazine | |
LU85847A1 (fr) | Amides et esters dihydropyridinyldicarboxyliques pharmaceutiquement utiles | |
CA1228359A (fr) | Procede de preparation de nouveaux derives de la quinoleine | |
CA1095047A (fr) | Procede de preparation de nouveaux derives du 1,4- benzodioxane | |
FR2753970A1 (fr) | Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique | |
JPS62155253A (ja) | グアニジノ安息香酸エステル誘導体 | |
CN115894456A (zh) | 一种氘代吡唑氨基嘧啶类化合物、药物组合物和用途 | |
EP0005091B1 (fr) | Nouvelles pipérazines monosubstituées, leurs procédés de préparation et les compositions pharmaceutiques les renfermant | |
CA1076117A (fr) | Procede d'obtention de nouveaux ethers aryliques et les produits en resultant | |
MXPA99006064A (en) | Acid-addition salts of optically active piperidine compound and process for producing the same | |
JPH10273464A (ja) | 置換カテコール誘導体 | |
EP2435406B1 (en) | Resolution of (±)-methyl phenyl[4-[4-[[[4'-(trifluoromethyl)-2-biphenylyl]carbonyl]amino]phenyl]-1-piperidinyl]acetate | |
EP3950688A1 (en) | Nitrogen-containing spiro derivative as ret inhibitor | |
KR19990079559A (ko) | 4-치환된 피페리디노테레프탈산 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97181039.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE GW HU ID IL IS KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2275987 Country of ref document: CA Ref document number: 2275987 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/006064 Country of ref document: MX Ref document number: 09331792 Country of ref document: US Ref document number: 1019997005802 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997949235 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1199900604 Country of ref document: VN |
|
WWP | Wipo information: published in national office |
Ref document number: 1997949235 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997005802 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997949235 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019997005802 Country of ref document: KR |